Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Frontline Plc Remuneration Information 2024

Nov 14, 2024

6242_rns_2024-11-14_f3c0d3c5-a323-4aa7-880a-3f9d202da2b9.pdf

Remuneration Information

Open in viewer

Opens in your device viewer

FRONTLINE PLC ANNUAL REMUNERATION REPORT 2023

Introduction

As a company incorporated in Cyprus and listed on the Oslo Stock Exchange, we are committed to providing transparency and accountability to our stakeholders. In accordance with the Directive 2007/36/EC, as amended by Directive (EU) 2017/828 (together, the "Directive"), we are pleased to present our remuneration report, which outlines the details of our executive remuneration and benefits package. The report has been prepared by the Board of Directors of Frontline plc in accordance with the Cyprus Stock Exchange ("CSE") Corporate Code of Governance 5th Editions (Updated) January 2019 and the requirements of the Encouragement of the Long-Term Active Participation of the Shareholders Law of 2021, Law 111(I)/2021.

The Report comprises remuneration to the Company's Chief Executive Officer ("CEO"), who has been employed by Frontline Management AS, a subsidiary of Frontline plc for the financial year 2023, along with members of the Board of Directors (the "Board"). For the year ended December 31, 2023 the reporting Company had no employees. The purpose of the Report is to provide a comprehensive, clear and understandable overview of awarded and due gross salary and remuneration to the Board for the last financial year.

The Company will present this report to the Annual General Meeting in 2024.

Remuneration committee

The Company established a Remuneration Committee in February 2023, comprising two independent directors, Mr. Ola Lorentzon and Mr. Marios Demetriades. Prior to its establishment, the remuneration of the CEO was determined by the Board with the overall objective to enhance shareholder value, by aligning the interests of shareholders and the CEO, as well as attracting and retaining qualified personnel.

The remuneration of the CEO is split between fixed and variable components. The variable component is split between sharebased compensation, linked to the long-term performance of the Company, along with a cash bonus, linked to the performance of the Company in the year. The fixed component, which includes salary and other benefits such as pension, is reviewed annually by the Board of Directors to ensure that it is aligned with the overall objectives of the Company's remuneration.

The Board of Directors

The remuneration of members of the Board consists of an annual fixed fee determined annually by the general meeting of the Company and to not exceed \$0.6 million in aggregate for the year ended December 2022 and grants under the Company's longterm incentive scheme as noted below. In addition, members of the audit committee receive additional fees for such service.

No variable remuneration has been reclaimed for the Directors or CEO in relation to the years ended December 31, 2023 or 2022.

Long-term incentive scheme

In December 2021, the Board approved the grant of 1,280,000 synthetic options to employees and board members according to the rules of the Company's synthetic option scheme approved on December 7, 2021. The synthetic options have a five-year term expiring in December 2026. The vesting period is 12 months for the first 27.5% of options, 24 months for the next 27.5% of options and 36 months for the final 45% of options. The synthetic options will be settled in cash based on the difference between the market price of the Company's shares on the date of exercise and the exercise price.

Summary of Company performance

Profit for the period increased by \$180.9 million in the year ended December 31, 2023 as compared to the year ended December 31, 2022. For a full analysis of the Company performance please see our Consolidated Financial Statements and Management report for the year ended December 31, 2023.

Total remuneration of the Directors and CEO

Name Position Start date End date
Ola Lorentzon Chairman and Non-Executive Director not applicable not applicable
John Fredriksen Non-Executive Director not applicable not applicable
James O'Shaughnessy Non-Executive Director and Audit Committee Chairman not applicable not applicable
Ole B. Hjertaker Non-Executive Director not applicable not applicable
Steen Jakobsen Non-Executive Director not applicable not applicable
Marios Demetriades Non-Executive Director and Audit Committee not applicable not applicable
Cato Stonex Non-Executive Director December 12, 2023 not applicable
Lars H. Barstad Chief Executive Officer of Frontline Management AS not applicable not applicable

Our Directors and CEO, along with start or end date to the extent applicable to the reporting period, are as follows:

Table 1 – Total remuneration of the Directors & CEO

Fixed Pension Proportion
(in thousands of \$) Base
salary
Fees Variable expense Total Proportion
fixed
variable
Ola Lorentzon 150 662 812 18 % 82 %
John Fredriksen 60 331 391 15 % 85 %
James O'Shaughnessy 70 331 401 17 % 83 %
Ole B. Hjertaker 60 60 100 % — %
Steen Jakobsen 60 60 100 % — %
Marios Demetriades 70 70 100 % — %
Cato Stonex 3 3 100 % — %
Lars H. Barstad 404 1,655 24 2,083 21 % 79 %
Total 404 473 2,979 24 3,880 23 % 77 %

Fixed fees are payable for services rendered as members of the Board of Directors.

Base salary is payable as remuneration for executive services.

Variable includes:

  • annual bonuses which have been paid or accrued during the reported financial year. Such bonuses are at the discretion of the Board.
  • the fair value of the synthetic options, as calculated based on the difference between the exercise price and market price of the underlying shares on the vesting date, which as a result of the fulfilment of predetermined performance criteria, were granted or offered in previous years but that vested during the reported financial year.

Pension expense includes the contributions that took place in the reported financial year to a defined contribution pension scheme.

In December 2021, the Board approved the grant of 1,280,000 synthetic options to employees and board members according to the rules of the Company's synthetic option scheme approved on December 7, 2021. The synthetic options have a five-year term expiring in December 2026. The vesting period is 12 months for the first 27.5% of options, 24 months for the next 27.5% of options and 36 months for the final 45% of options. The exercise price is NOK 71, which shall increase by NOK 5 on each of December 7, 2023, and December 7, 2024, and will further be adjusted for any distribution of dividends made before the relevant synthetic options are exercised. The synthetic options will be settled in cash based on the difference between the market price of the Company's shares and the exercise price on the date of exercise. The synthetic options are not subject to a retention period.

The below table details the number of options granted to each individual in respect of the three vesting periods noted above:

Closing balance
Name Vesting date Options held at
the beginning of
the year
Options exercised Options held at
the end of the
year
Ola Lorentzon 07/12/2022 44,000 (44,000)
Ola Lorentzon 07/12/2023 44,000 44,000
Ola Lorentzon 07/12/2024 72,000 72,000
John Fredriksen 07/12/2022 22,000 22,000
John Fredriksen 07/12/2023 22,000 22,000
John Fredriksen 07/12/2024 36,000 36,000
James O'Shaughnessy 07/12/2022 22,000 22,000
James O'Shaughnessy 07/12/2023 22,000 22,000
James O'Shaughnessy 07/12/2024 36,000 36,000
Lars H. Barstad 07/12/2022 110,000 110,000
Lars H. Barstad 07/12/2023 110,000 110,000
Lars H. Barstad 07/12/2024 180,000 180,000
Total 720,000 (44,000) 676,000
Closing balance
Name Vesting date Options awarded
and unvested
Options vested Options awarded
and unvested
Ola Lorentzon 07/12/2023 44,000 (44,000)
Ola Lorentzon 07/12/2024 72,000 72,000
John Fredriksen 07/12/2023 22,000 (22,000)
John Fredriksen 07/12/2024 36,000 36,000
James O'Shaughnessy 07/12/2023 22,000 (22,000)
James O'Shaughnessy 07/12/2024 36,000 36,000
Lars H. Barstad 07/12/2023 110,000 (110,000)
Lars H. Barstad 07/12/2024 180,000 180,000
Total 522,000 (198,000) 324,000

At the grant date, the Company's underlying share price was NOK 65. On December 7, 2022, the date on which the first tranche of synthetic options vested, the Company's underlying share price was NOK 123.60. On December 7, 2023, the date on which the second tranche of synthetic options vested, the Company's underlying share price was NOK 209.30.

Comparative information on the change of remuneration

(in thousands of \$) 2023 vs
2022
2022 vs
2021
2021 vs
2020
2020 vs
2019
2019 vs
2018
Change in remuneration
Non-executives
Ola Lorentzon 36 54
John Fredriksen (36) (54)
James O'Shaughnessy (15) (34) 49 51
Ole B. Hjertaker 20 40
Steen Jakobsen 20 40
Marios Demetriades 55 15
Tor Svelland (41) (19) 40 20
Jens Martin Jensen (34) 34
Cato Stonex 3
Other non-executives (47) (23)
Executives
Lars H. Barstad (195) 264 295 64
Other executives (963) (49) 22
Total (187) 340 (626) 12 73
Change in Company performance
Change in profit or loss for the period 180,877 490,498 (427,836) 272,903 148,852

The calculation includes fees, salary, bonus, pension and other benefits payable to directors and the CEO by the Company and its subsidiaries. The calculation excludes share-based variable remuneration for directors and the CEO of the Company. "Other non-executives" is comprised of remuneration paid to those directors not remunerated in the reported financial year. "Other executives" is comprised of remuneration paid to other executive officers not remunerated in the reported financial year.

Profit is derived from our consolidated financial statements prepared in accordance with International Financial Reporting Standards for the years ended December 31, 2023, 2022 and 2021. Profit for the years ended December 31, 2020, 2019 and 2018 is derived from our consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America.